ASX Release No.

673 26 November 2013 Page 1 of 1

ACN 090 987 250

ASX Release


SUDA LTD: INVESTOR ROAD SHOW
PRESENTATION

PERTH, AUSTRALIA - 26 November 2013: SUDA LTD (ASX: SUD) today announces
that Mr. Stephen Carter, Executive Chairman and CEO, and Mr. Nick Woolf, Chief
Business Officer, are presenting to institutional investors, brokers and analysts in Adelaide,
Melbourne and Sydney from 26 - 29 November 2013. The investor presentation follows.



Further information:
STEPHEN CARTER
EXECUTIVE CHAIRMAN
SUDA LTD
Tel: +61 8 6142 5555
sjcarter@sudaltd.com.au

NOTES TO EDITORS:
About SUDA LTD
Suda Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in
Perth, Western Australia. The Company is developing low-risk oral sprays using novel formulations of
existing off-patent pharmaceuticals. The many potential benefits of administering drugs through the oral
mucosa (ie: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and
faster response time. Sudas most advanced product is a novel sub-lingual treatment, ArTiMist, for severe
malaria in children. In a Phase III trial, ArTiMist was shown to be superior to intravenous quinine. Other
development stage products include orals sprays for the treatment of migraine headache, erectile dysfunction
and chemotherapy-induced nausea and vomiting.
november 2013
1
1
!"#$ &'()*'"+ ,-".#$- ,-' ."/( 0#1.2/
SLephen CarLer - Lxecuuve Chalrman & CLC
nlck Woolf - Chlef 8uslness Cmcer

november 2013

Level 1, unlL 12, 33 Powe SLreeL
Csborne ark, WesLern AusLralla 6017
C 8ox 1719
Csborne ark 8C, WA 6916
(1) +61 8 6142 3333
(l) +61 8 9443 8838
(L) suda[sudalLd.com.au

2
CvL8vlLW
! SuuA (ASx: Suu) ls a drug dellvery company commerclallslng low-rlsk
pharmaceuucals
! World-leadlng Lechnology for reformulaung drugs lnLo oral sprays wlLh
fasLer onseL of acuon
! Muluple paLenL famllles coverlng approx. 300 wldely-used o-paLenL drugs
! 8reakLhrough sub-llngual spray for LreaLmenL of chlldren wlLh severe
malarla - compleLed hase lll Lrlal
! Muluple oral sprays for large malnsLream markeLs - mlgralne, erecule
dysfuncuon, chemo-lnduced nausea
! SLraLegy for rapld commerclallsauon Lhrough Lrade sales or collaborauons

november 2013
2
3
C8C-MuCCSAL uLLlvL8? - 8L11L8 A1lLn1
LxL8lLnCL
! Cral mucosa ls Lhe llnlng of Lhe mouLh, rlchly supplled by blood vessels
! Cral cavlLy ls ldeal for sysLemlc Lherapy, avolds meLabollsm ln Lhe guL
! unlque advanLages of oral sprays compared Lo LableLs
" lasLer onseL of acuon
" 8educuon ln dose level and dose varlablllLy
" Lnhanced pauenL convenlence
" Avolds Lhe need Lo swallow or be Laken wlLh waLer
1,2
!"#$ &$'( )*$'+)
*&,-./'((+ &0-$ 12*$&3-4
-56'6+ '.4 ' 7-8-$
&#,6&2- 9&$ *'/-.,):
1. >40 of adulLs experlence dlmculues swallowlng
2. >30 of chlldren (6 Lo 11 years) have problems swallowlng LableLs
4
C8C-MuCCSAL uLLlvL8? - 8LnLll1S lC8 PA8MA
! AdvanLages of oral sprays Lo pharmaceuucal
companles
" aLenLed dellvery Lechnology proLecLs agalnsL
generlc compeuuon
" 8egulaLory paLh can provlde markeL excluslvlLy
" new oral spray formulauon can exLend or expand
exlsung franchlse
" Superlor producL prole allows for premlum prlclng
and sLrong markeL peneLrauon
" lmproved ouLcome for pauenL supporLs
relmbursemenL from payers
november 2013
3
3
C8C-MuCCSAL uLLlvL8? - LCW-8lSk 8LCuLA1C8?
A1P
! SLraLegy Lo Lake advanLage of fasLer and less expenslve regulaLory paLhways
! luA's 303(b)(2) leglslauon deslgned for reformulauons of luA-approved drugs
" Leverage luA's exlsung daLa on safeLy and emcacy of orlglnal drug
" Slmply demonsLraLe bloequlvalence of reformulauon vs. orlglnal drug
! 303(b)(2) producLs are lncenuvlsed wlLh 3-3 years markeL excluslvlLy ln uSA
! MosL counLrles have adopLed slmllar regulaLory paLhways Lo Lhe luA
6
CCMlA8AuLL CCLLAuC8A1lCl/18ALL SALL LLALS
Cene|c Lug Sumat|otan M|oazo|am Cnoanseton .o|o|oem
Le||vey 1ec|no|ogy lasa| soay Ca| bucca| soay Ca| so|ub|e |m Sub||ngua| tab|et
L|sease M|ga|ne Se|zues lausea/vom|nng lnsomn|a
L|censo/L|censee Connose/Avan| Aua||s/v|ol|ama MonoSo|/Stanva Cexo/MLLA
1e|toy lot| Ame|ca C|oba| bSA C|oba|
boont layment bS$20M bS$1SM bS$3M bS$13M
M||estones bS$90M bS10M bS$24M bS$90M
8oya|nes on Sa|es ?es, neeo lo ?es, neeo ?es, ooub|e o|g|t
Late S|gneo !u|y 2013 May 2010 Seot 2008 Ao|| 2008
S18A1LC? lC8 C8C-MuCCSAL LA1lC8M
! 8eformulaLe o-paLenL pharmaceuucals lnLo hlgh-value paLenLable oral sprays
! uemonsLraLe advanLages over sLandard of care ln proof-of-concepL small Lrlals
! CollaboraLe or Lrade sale Lo pharma for reglsLrauon and markeung
! AnuclpaLe rsL ma[or deals ln P2 C?2014
november 2013
4
7
roducL
Acuve
lngredlenL
MarkeL
Slze
Markeung
Approval
Cllnlcal
re-
cllnlcal
Malarla AruMlsL` >$300m
Mlgralne headache Suu-001 $3.2bn
re-procedural
anxleLy
Suu-003 $170m
ChemoLherapy lnduced
nausea & vomlung
Suu-002 $2.3bn
Lrecule dysfuncuon
Suu-003
uuroMlsL`
$4.1bn
ulmonary arLerlal
hyperLenslon
Suu-004 $2.7bn
ArLemeLher
SumaLrlpLan
Mldazolam
CndanseLron
Slldenal
Slldenal
LCW-8lSk lLLlnL 1A8CL1lnC LA8CL MA8kL1S
8
A81lMlS1` An1l-MALA8lAL S8A?
! Ar1lMlsL` subllngual arLemeLher for chlldren wlLh severe malarla
! CompleLed hase lll Lrlal versus lnLravenous qulnlne ln AugusL 2013
" 130 chlldren from muluple slLes ln Afrlca
" ConducLed Lo hlghesL sLandards for use ln worldwlde regulaLory submlsslons
! rlmary endpolnLs were achleved showlng superlorlLy Lo qulnlne
" Ar1lMlsL` reduced paraslLe counL by >90 ln 96 of pauenLs ln 24 hours vs.
41 of pauenLs LreaLed wlLh qulnlne
" araslLe clearance ume 30 hours wlLh Ar1lMlsL` vs. 68 hours wlLh qulnlne
1hompson 8euLers ldenued
Ar1lMlsL` as one of Lhe
world's 1op-3 mosL promlslng
hase lll drugs ln 2011

november 2013
3
9
A81lMlS1` MCvlnC 1C CCMML8ClALlSA1lCn
! Successfully compleLed manufacLurlng scale-up wlLh Canadlan manufacLurer
! llnallslng regulaLory documenLauon for markeung appllcauons
! Clobal rlghLs and l owned by SuuA -conLrolled company
! LsLabllshlng Sclenuc Advlsory 8oard Lo advlse on expandlng producL poLenual
! AppolnLed lnLernauonal buslness developmenL consulLancy - 1orreya
! AnuclpaLe Lrade sale or collaborauon ln P2 C?2014

!;$<1=1),> ?') ?#@- *&,-./'(
') '. -'$(+ 1.,-$3-./&.'(
,$-',2-., 9&$ 6?1(4$-. A1,?
)-3-$- 2'('$1':
10
A81lMlS1` MA8kL1 CC81unl1?
! 1yplcal scenarlo ln Afrlcan vlllage (several mllllon per year)
" 3 year old chlld develops severe malarla
" uehydraLed, vomlung, dlarrhoea, rapld cllnlcal deLerlorauon
" 1reaLmenL opuons: LableL, supposlLory or qulnlne ln[ecuon
" vomlung and dlarrhea make LableLs and supposlLorles dlmculL Lo admlnlsLer
" Culnlne ln[ecuon requlres Lralned medlcal sLa and hosplLallsauon
! Ar1lMlsL` requlres no medlcal Lralnlng and can be admlnlsLered ln vlllage
" no cold sLorage and no needles requlred
World PealLh Crganlsauon
reporLs 640,000 deaLhs annually
from malarla. 1he LanceL
medlcal [ournal esumaLes
double LhaL gure
november 2013
6
11
Suu-001 lC8 MlC8AlnL PLAuACPL
! Suu-001 ls rsL oral spray of sumaLrlpLan (CSk's lmlLrex LableL or nasal spray)
for rapld rellef of mlgralne headache
! Mlgralne markeL ls approx $3.2 bllllon. SumaLrlpLan has 30 markeL share
! 1wo Suu-001 Lrlals ln approx 43 pauenLs showed safeLy and superlorlLy Lo
lmlLrex 30mg LableL
" SlgnlcanLly greaLer reducuon ln headache paln wlLh 30mg & 40mg Suu-001 spray
" SlgnlcanLly more pauenLs responded Lo Suu-001 vs. lmlLrex aL 60 mlnuLes
! lvoLal Lrlal could supporL reglsLrauon
! lasLer onseL of acuon provldes compeuuve advanLage
Suu-001 has superlor prole Lo
markeL leadlng lmlLrex LableL
12
Suu-002 lC8 CPLMC1PL8A?-lnuuCLu nAuSLA
& vCMl1lnC
! Suu-002 ls rsL oral spray of ondanseLron (CSk's
Zofran LableL) Lo LreaL nausea & vomlung lnduced
by chemoLherapy or radloLherapy
! Clobal anu-emeucs markeL ls approx. $2.3 bllllon
! Suu-002 evaluaLed ln >300 pauenLs ln muluple Lrlals
vs. 8mg Zofran LableL
" Suu-002 spray was safe, well LoleraLed and
bloequlvalenL Lo LableL
" SlgnlcanLly fasLer absorpuon of drug wlLh 8mg
Suu-001 spray vs. 8mg Zofran LableL
! Lxlsung cllnlcal daLa poLenually sumclenL for
reglsLrauon
! 1ableLs are noL ldeal when pauenLs are vomlung
! lasLer absorpuon provldes compeuuve advanLage
Suu-002 has
superlor prole Lo
markeL leadlng
Zofran LableL
november 2013
7
13
Suu-003 lC8 L8LC1lLL u?SlunC1lCn
! Suu-003 (uuroMlsL`) ls a meLered oral spray of slldenal (zer's vlagra
LableL) for erecule dysfunuon
! Lu markeL ls >$4 bllllon. vlagra ls world's Lop selllng Lu drug
! Worldwlde (exc. uSA) generlcs launched buL no oral spray formulauons
! uuroMlsL` Lrlal ln 24 males showed safeLy and bloequlvalence vs. vlagra
" 20mg uuroMlsL` spray was bloequlvalenL Lo 23mg vlagra LableL
! lvoLal Lrlal could supporL reglsLrauon
! oLenual fasLer onseL as dlrecL absorpuon avolds meLabollsm ln guL
uuroMlsL` oers ease of
admlnlsLrauon and poLenually
fasLer onseL of acuon Lhan
vlagra LableL
14
Lx1LnSlvL A1Ln1 LS1A1L
! Muluple paLenL famllles & more pendlng, coverlng:
" 300 hlgh-usage exlsung drugs formulaLed lnLo oral sprays
" 1echnology for produclng 'mlcro-mlsL' formulauon
" ump (alr-acuvaLed) & aerosol (propellanL-drlven) sprays
" Mulu-dose or slngle-unlL conLalners
! aLenL Lerm of cerLaln famllles exLends Lo 2031
november 2013
8
13
WLS1CCAS1 Su8ClCAL - 8Alu C8CW1P
! Wholly-owned subsldlary ls a sales and loglsucs operauon for medlcal
devlces and consumables based ln WesLern AusLralla
! Lxperlenclng rapld revenue growLh from recenL conLracL ln AugusL 2013
! 1C l?2014 revenue of $3.3 mllllon, >200 lncrease from C
! 1C l?2014 neL proL of $720,000 compared Lo a loss ln Lhe C
WesLcoasL has enLered a new era ln lLs
operauons. Cur posluve cash ow wlll
conLrlbuLe slgnlcanLly Lo Lhe nanclal
susLalnablllLy of our parenL, Suda LLd"
16
ASx Cooe SbL
Cuent s|ae o|ce $0.0S
S2 wee| ange $0.024-$0.0S1
Aveage vo|ume (30-oay) 3.1 m||||on
Ma|et cao $4S m||||on
l|nanc|a|s
8evenue 1 l?2014
let oot 1 l?2014
let cas|

$3.3 m||||on
$0.2 m||||on
$S.9 m||||on
Ct|e luno|ng $3.6 m||||on equ|ty ||ne o ceo|t
Cao|ta| Stuctue
S|aes on |ssue
Convenb|e lotes
Conons

89S m||||on oo|nay s|aes

$3.0 m||||on convenb|e to esnmateo 106.4 m||||on s|aes
S2 m||||on Q $0.0S exec|se o|ce
kL? uA1A & llnAnClAL SnASPC1
november 2013
9
17
Al1lCllA1LL LvLl1 Al1lCllA1LL 1lMllC
l|na||se A1|M|st egu|atoy oocumentanon l1 C?2014
Conouct o|may eseac| on ma|et ooootun|nes l1 C?2014
ln|nate outeac| to l|ama |nousty l1 C?2014
A1|M|st taoe sa|e o out-||cens|ng oea| l2 C?2014
l|st mao oo-mucosa| out-||cens|ng oea| l2 C?2014
CCMML8ClALlSA1lCn CCALS
! loundauons are seL for rsL ma[or deals ln C?2014
!B- ?'3- -),'7(1)?-4 ' 4--* *1*-(1.-
&9 &$'( )*$'+) 7')-4 &. &#$ &$&C
2#6&)'( 4$#@ 4-(13-$+ *('D&$2:
18
LxL8lLnCLu 8CA8u & MAnACLMLn1
! SLephen CarLer - Chalrman and Chlef Lxecuuve Cmcer
# 23 years' pharmaceuucal lndusLry experlence wlLh mulu-nauonal pharmaceuucal
and llsLed publlc companles
! Mlchael SLewarL - non-Lxecuuve ulrecLor
# 8road corporaLe and managemenL background and lnvolvemenL ln bllaLeral donor
funded and World 8ank co-nanced ald pro[ecLs
! ken 8obson - non-Lxecuuve ulrecLor
# 8ackground lncludes exLenslve experlence as a corporaLe lawyer and advlsor,
speclallslng ln fundralslng, compllance and mergers & acqulsluons
! !oseph Chayon - Chlef llnanclal Cmcer and ulrecLor
# 20 years' experlence ln nanclal roles lncludlng 12 years wlLhln healLh-relaLed
lndusLrles
! nlck Woolf - Chlef 8uslness Cmcer
# 20 years' experlence ln pharma/bloLech lnvesLmenL banklng and lndusLry wlLh
exLenslve buslness developmenL knowledge
november 2013
10
19
SuMMA8?
! World-leadlng proprleLary Lechnology for reformulaung drugs lnLo hlgh-
value oral sprays
! 8reakLhrough anu-malarlal spray progresslng Lowards commerclallsauon
! lpellne of oral sprays oerlng superlor proles (eg: fasLer onseL) Lhan
sLandard of care
! 1argeung large markeLs wlLh shorL umellnes for developmenL
! 8apld value creauon Lhrough collaborauons or Lrade sales, anuclpaLed ln
nexL 12-18 monLhs